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ABSTRACT 
COVID-19 presents a great threat to public health worldwide and the infectious agent SARS-CoV-
2 is currently the target of much research aiming at inhibition. The virus’ main protease is a 
dimeric enzyme that has only recently begun to be thoroughly described, opening the door for 
virtual screening more broadly. Here, a PAIN-filtered flavonoid database was screened against 
four sites of the protease: a free (normal) conformation of the Substrate Binding Site (NSBS), an 
induced-fit state of the SBS (ISBS), a Dimerization Site (DS) and a Cryptic Site (CS). The mean 
binding energy of the top five ligands from each site were -9.52, -11.512, -7.042 and -10.348 
kcal/mol for the NSBS, the ISBS, the DS and the CS, respectively. For the DS and CS, these top 
five compounds were selected as candidates to bind their respective site. In the case of SBS, the 
top 30 ligands with the lowest binding energies from NSBS and ISBS were contrasted and the 
ones present in both lists were selected as the final candidates.  The final list was: Dorsilurin E 
(FL3FQUNP0001), Euchrenone a11 (FL2FALNP0014), Kurziflavolactone C (FL2FA9NC0016), 
Licorice glycoside E (FL2F1AGSN001) and Taxifolin 3'- (6"-phenyl- acetylglucoside) 
(FL4DACGS0020) for the SBS; Sanggenol O (FL2FALNP0020), CHEMBL2171573, Kanzonol E 
(FL3F1ANP0001), CHEMBL2171584 and Abyssynoflavanone VI (FL2FACNP0014) for DS and 
CHEMBL2171598, CHEMBL2171577, Denticulaflavanol (FL5FAANR0001), Kurzichalcolactone 
(FL1CA9NC0001) and CHEMBL2171578 for CS. Virtual screening integrated several confirmation 
methods, including cross-docking assays and positive and negative controls. All 15 compounds 
are currently subjected to molecular dynamics so as to theoretically validate their binding to the 
protease. 
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1. INTRODUCTION 
The Coronavirus Disease-2019 (or COVID-19) was first reported in late December 2019 in 
Wuhan, PRC (1). First identified as a kind of pneumonia, common symptoms are fever, cough 
and myalgia or fatigue, with less common symptoms ranging from sputum production, 
headache, haemoptysis and diarrhoea (2).  Later developments included lymphopenia and 
dyspnoea. These findings point at a clinical description akin to that of severe acute respiratory 
syndrome (SARS) coronavirus (2,3). 
Nonetheless, finding a treatment for viral diseases seldom is a serendipitous event. It requires 
systematic narrowing of candidates, usually by virtual screening (VS) methods. VS has been able 
to provide ample and robust support for drug discovery, design and evaluation efforts (4,5) with 
a variety of specialized options (6) as the in silico counterpart for high throughput screening. 
These are often coupled in sequential or parallel arrays: hierarchical VS (HLVS) or parallel VS 
(PVS), respectively (5). This development was inevitable given both the relentless growth in 
library sizes (7,8) and the equally vertiginous development in the virtual screening par 
excellence, molecular docking (9–11). HLVS has been invaluable in sieving through large 
databases of small organic molecules to find drugs for viral diseases. This is invaluable for the 
development of new contenders as the current pharmacological options are rendered obsolete 
by high viral genome variability (12). Such developments of new drugs against virus through VS 
include influenza (13), ebola (14) and dengue (15). 
Trying SARS-CoV drugs against SARS-CoV-2 has been proposed (16) given the close genomic 
proximity between them (17). Unfortunately, those drugs have not been universally approved 
for treatment and usually remain stagnant on clinical or pre-clinical trials (18). Moreover, even 
small differences in amino acid sequence can affect drug efficaciousness (19). Unsurprisingly, 
the appeal of VS approaches against SARS-CoV-2 has not eluded scientists during this pandemic. 
Most have tried to evaluate the repurposing of existing drugs (16,20–22). Nevertheless, these 
research lines run the risk of facing adverse effects later on for employing drugs designed for 
other sites (23). Other papers have focused on the active site of SARS-CoV-2 main protease 
(MPRO) (16,24), but this emphasis could be too restrictive since dimerization inhibition is a 
plausible alternative  (25,26).  Furthermore, the occurrence of cryptic sites is a possibility worth 
exploring. Loosely put, a binding site can be described as cryptic if identifiable in the ligand-
bound while not in the unbound structure of a given protein (27).  These locations pose a 
promising way to increase the druggability of a target protein (28,29). Therefore, an exhaustive 
VS of readily available, pharmacologically safe, new small molecules targeted at more than one 
site in the MPRO is the aim of this paper. 
Flavonoids are one such group of small molecules produced as secondary metabolites in fungi 
and plants. They present a common diphenyl structure coupled with a heterocyclic ring and with 
various hydroxyl phenolic groups with great chelation capacity for iron and other transition 
metals. Especially relevant to this research is the antiviral activity of flavonoids. The flavonoid 
apigenin combined with acyclovir has a significant effect on types 1 and 2 herpes virus simplex 
known since the early 1990s (30). Remarkably, 64 flavonoids were previously screened against 
the SARS-CoV-1 3CL (chymotrypsin-like) protease (3CLpro) with promising results (31). 
Furthermore, the 3CLpro from SARS-CoV-1 differs from the SARS-CoV-2 MPRO in but 12 amino 
acids, which justifies a further attempt for flavonoid inhibition against this second protein (32). 
In that vein, a handful of flavonoids have been recently tried in silico against SARS-CoV-2 spike 
protein (33), which leaves open the questions as to what other flavonoids could prove useful. 
All this considered, the panoply of flavonoids available in many online databases presents itself 
as an ideal opportunity to fuel a new quest for SARS-CoV-2 inhibition. 
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2. METHODS 
2.1. Generation of 3D structures and selection of putative binding sites 
2.1.1. Library preparation 
An exhaustive search was conducted for compounds reported as flavonoids in the Metabolomics 
(34) database with an inhouse R script for web scraping using the rvest package (35). Similarly, 
the online databases DrugBank (36), CHEMBL (37) and PubChem (38) were subject to an 
automated search. For these last websites, searches were performed manually with the key 
words flavonoid, flavonoids and flavo, except for DrugBank, where the whole base was 
downloaded. Then, all four bases were standardized to show a unique ID, SMILE and online 
source for each compound. All four databases from DrugBank, PubChem, CHEMBL and 
Metabolomics were merged through an R script, additionally parsing the complete database 
through the same means in order to remove compounds with molar weight under 180 kDa. 
Compounds with identical SMILES were removed for each database. 
2.1.2. PAINs filtering 
The database was then uploaded to FAFDrugs4 server (39) for further processing. Two SMILES, 
even though literally distinct, may be synonyms for the same compound. FAFDrugs4 reads each 
SMILE and interprets the code into structure in order to exclude synonymic SMILEs. Next, all 
screening tools to identify and purge pan-assay interference compounds (PAINS) offered by the 
website were employed. A final SMILE database was downloaded and matched for their unique 
IDs and online sources. 
2.1.3. 3D structure generation. 
SMILEs were read and employed to generate .smi files for each compound. Afterwards, these 
files worked as blueprints for the generation of .sdf files containing the bidimensional structure 
of each compound through the package OpenBabel v.3.1.1 (40). These in turn were the starting 
point for the three-dimensional structures, each of which was subject to a 25000-step 
minimization through the steepest-descent method (41). Finally, the resulting .sdf files of the 
minimized compounds were converted to .pdb format for their docking preparation. All these 
steps were performed automatically through an inhouse Python script. 
2.1.4. Electrochemical and structural assessment of putative binding sites 
Three sites of interest were identified for docking targeting: the substrate-binding site (SBS), the 
dimerization site (DS) and the cryptic site (CS). The first two were chosen after bibliographic 
consideration (32,42) while the cryptic site was originally predicted using CryptoSite (28). 
Collectively, they are referred to as “putative binding sites”. 
pH is not homogeneously distributed along the protein surface, given that pH in each region is 
determined by the microenvironment fostered by the residues specific to that region. In order 
to analyse these microenvironments, server PDB2PQR (43) was employed. Said program assigns 
the appropriate protonation states to an input protein’s residues, presently the apo-structure 
of MPRO excised from PDB ID: 6LU7. This software takes into account the surrounding residues 
as well as the macro-system pH, which in this case was set to 7.4 (physiological pH). Thus, the 
protonation states of key histidines were employed to infer the microenvironment pHs for the 
three putative binding sites and where they stood in comparison to the general pH of the 
system.  
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Each putative binding site had its respective solvent-accessible surface area (SASA) found in 
PyMol v.2.4 (44), using as input the hydrogen-curated structure of MPRO obtained before. All the 
regions were scoured for residues capable of establishing strong interactions, aromatic rings and 
other relevant moieties. The exact residues which conform the S1’ and S1-S5 subsites of the SBS 
region (42,45) were determined by analysis of MPRO-N3 complex (PDB: 6LU7). 
2.2. Docking assays 
2.2.1. Ligand preparation. 
20 random compounds were selected in order to conclude the structure was correctly 
represented. Once this was settled, the files were converted from .pdb to .pdbqt format with 
the AutodocksTool v.4.2 package (46). All torsions were assigned and Gasteiger charges were 
added for all atoms in the compound structures. 
2.2.2. Receptor preparation. 
MPRO structure was procured in two distinct conformations: a free conformation (PDB: 6YB7) and 
another conformation induced by an inhibiting ligand in the active site (PDB: 6LU7). These 
structures were independently curated on PDBfixer (47) with the intent of repairing lost atoms 
and non-standard residues, as well as for deleting heteroatoms. Using this repaired chains, both 
receptors were constructed as dimers from the available protomeric states in their respective 
.pdb files (biological assembly) using PyMol software.Then, all receptor structures were 
converted to .pdbqt format using the graphic interface found in the AutodockTools v.4.2 
package, adding polar hydrogens and Gasteiger charges as well. 
2.2.3. Virtual Screening. 
For the following procedure, a semiflexible VS (with rigid receptor and flexible ligand) was 
conducted so as to assess the possibility of compound interaction with each putative binding 
site. For this purpose, Autodock Vina v.1.1.2 (48) software was employed with 24 of 
exhaustiveness (49) through a Python script which automated the task. 
2.2.3.1.          SBS 
In order to reach robust conclusions for SBS-binding compounds, a cross-docking methodology 
was followed. To this end, the receptors were free MPRO (PDB: 6YB7) and ligand-induced 
conformation MPRO (PDB: 6LU7).  All residues conforming the SBS were included within the 
volume of the search box. Box coordinates for normal and induced-fit docking were 12.339, 
1.287, 23.152 and -15.117, 14.564, 67.870; respectively. Dimensions for both boxes were kept 
at 35 Å x 35 Å x 35 Å for minimizing search bias. 
2.2.3.2.          DS and CS 
Given that no induced conformations were available for DS or CS, no cross-docking was 
performed, keeping free MPRO as the receptor. Box coordinates for DS and CS were 1.738, -3.380, 
4.457 (22 Å × 28 Å × 36 Å) and 9.104, 12.126, -6.685 (30 Å × 40 Å × 30 Å); respectively. 
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2.3.   Validation 
2.3.1.     Validation docking 
In order to confirm VS results, the next step was a validation docking (VD) with more exhaustive 
parameters using the top 100 best compounds in Autodock-GPU v.4.2 (50). Lamarckian genetic 
algorithm (LGA) was used as a global search method, while the local search was directed after 
the Solis-Wets algorithm (SWA). The procedure included 25 million evaluations and 150 runs. 
Box coordinates were maintained irrespective of each virtual screening, with 0.375 Å spacing. 
Dimensions were 18.75 Å × 18.75 Å × 18.75 Å, 22.5 Å × 30 Å × 37.5 Å, and 30.375 Å × 40.5 Å × 
30.375 Å for the SBS (both NSBS and ISBS), DS and CS VDs, respectively. 
For each docking assay, the best pose was selected based on its 2Dscore (51). Briefly, each pose 
is assigned a score based on the standard normalization (Zscore) of two variables: binding 
energy (ΔG) and cluster population (Pop). Said score is calculated as follows: 
2𝐷"#$%& 	= 	−1× [𝑍"#$%&(𝛥𝐺)] + 𝑍"#$%&(𝑃𝑜𝑝) 
The selected solutions were then ranked according to their binding energies. For the DS and CS 
VDs, the top five ligands with the lowest binding energies were selected as hits. In the case of 
SBS, the top 30 ligands with the lowest binding energies from the VDs against NSBS and ISBS 
were contrasted and the ones present in both lists were selected as hits. Then, their most 
favourable pose was extracted using PyMol, converted to .mol2 format and supplemented with 
the missing hydrogen atoms using OpenBabel at pH 7.4. The protein-ligand complex was 
reconstructed by merging the ligand file with its corresponding hydrogen-curated receptor (see 
Section 1.3 above). 
2.3.2.     Positive and negative controls 
It is key to confirm that the docking workflow can replicate the binding event of a known 
experimental inhibitor and provide reference values (positive control). To this end, the potent 
broad-spectrum non-covalent SARS-CoV-2 inhibitor X77 was chosen as comparative standard. 
The ligand (X77) was excised from a X77-MPRO co-crystallized complex (PDB: 6W63) using PyMol, 
while the same was done for the receptor (free MPRO) from a N3-MPRO co-crystallized complex 
(PDB: 6LU7). Then, the ligand .pdb file was converted into .sdf using OpenBabel v.3.1.1. This file 
was curated manually using PyMol again so as to correct bond order and add missing hydrogen 
atoms. X77 was then docked against ISBS in order to produce a cross-docking while maintaining 
the last VD’s parameters. The resulting complex was contrasted with the initial structure (PDB: 
6W63) by their RMSD using PyMol (52). 
Equally important is the capacity of sieving protocols for rejecting inert molecules. These 
compounds could exhibit false positives in biochemical assays due to colloidal aggregation 
(53,54). This is the case of TDZD-8, which only inhibits MPRO through aggregation (45). Thus, this 
molecule is taken as an appropriate negative control to test the efficacy of the present protocol 
at excluding unspecific, promiscuous molecules. Again, the docking of this compound follows 
the VD protocol explained before. 
2.4.   Protein-ligand interaction analysis 
Protein–Ligand Interaction Profiler (PLIP) was used with default parameters to further explore 
protein-ligand interactions arising from docking (55). Coupled with previous electrochemical-
structural revision, PLIP shed light on the chemical environment surrounding each flavonoid. 
 5 
Regarding the SBS, it is worth mentioning that only the interactions provided by the VD against 
ISBS were identified and analysed. 
In addition to these steps, the protein-ligand complex .pdb files for each hit (see Section 2.3.1 
above) was uploaded to the online service Dr. SASA (56) in order to obtain surface data. 
3.  RESULTS 
3.1.   Flavonoid Structural Database 
The complete database (before FAFDrug4 filters) included 6696 compounds. The final database 
comprised 4887 compounds. SMILE information for every compound sufficed to generate 
satisfactory minimized 3-D structures in .pdbqt format. The approximate mean torsion quantity 
was 9.73. Exhaustiveness was adjusted to 24 for Vina VS and the number of evaluations was set 
to 25 million for the VD as a higher number of torsions requires deeper search standards. 
3.2.   Cryptic Site Description 
Cryptic site prediction was done through CryptoSite, which produces a .pol.pred file containing 
prediction scores for every residue. The residue is presumed to have a high probability of 
constituting a cryptic site whenever the score is above 10. Out of these, several were also 
present in the same region as the SBS or DS boxes or relatively close to their residues. These 
were left out for the sake of dynamic independence. The residues comprising CS are Lys5, Met6, 
Pro108, Gly109, Arg131, Trp218, Phe219, Tyr239, Glu240, Leu271, Leu272, Leu287, Glu288, 
Asp289, Glu290, Arg298, Gln299 and Val303. 
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3.3.   Analysis of Putative Binding Sites 
Figure 1. The MPRO of SARS-CoV-2 and its putative binding sites. Monomers are in cartoon and surface representations, each one 
in a different colour. The region covered by each putative binding site in the green monomer is shown as a black rectangle. Residues 
conforming the sites are depicted as sticks along their names. (a) Substrate binding site, with colours representing subregions: red 
for S1’, blue for S1, purple for S2, orange for S3, grey for S4 and cyan for S5. Catalytic residues are marked with an asterisk. (b) 
Dimerization site. (c) Cryptic site. 
MPRO is a homodimer with a heart-shaped structure (Figure 1). The SBS region of MPRO can be 
further subdivided into S1’ and S1-S5 subsites. Respectively, these sites interact with P1’ and P1-
P5 segments of a generic substrate peptide (42). S1’ is defined to be the catalytic region. Other 
segments of the peptide are numbered consecutively, starting from P1’. According to this 
definition, it is possible to map S1’ and S1-S5 subsites by analysing the MPRO-N3 interaction 
described elsewhere (45). Shortly, the S1’ subsite comprises His41, Gly143, Ser144 and Cys145; 
S1 includes Ser1 (from the other protomer), Phe140, Leu141, Asn142 and His163; S2 consists in 
Met49, Tyr54, His164, Asp187 and Arg188; S3 consists in Met165 and Glu166; S4 is constituted 
by Leu167, Gln189, Thr190 and Gln192; and S5 encompasses Pro168 and Ala191 (Figure 1a). All 
of these residues are part of, but not limited to the ones reported in the literature (32). 
Regarding dimensions, SBS has a SASA of 975.013 Å2. Two histidine tautomers may exist under 
physiological conditions: HSD (protonated in the delta position) with a pKa of 6.7, and HSE 
(protonated in the epsilon position) with a pKa of 7.3 (57). In the SBS, three monoprotonated 
histidines were found: His41 and His163 (HSD) and His164 (HSE). Apart from histidines, three 
amino acids with charged side chains at physiological pH were observed within the site (Table 
1). Lastly, Cys145 forms a catalytic dyad with His41. 
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The following residues constitute the DS with a 
joint SASA of 736.627 Å2: Arg4, Met6, Ser10, 
Gly11, Glu14, Asn28, Ser139, Phe140, Ser147, 
Glu166, Glu290 and Arg298 (Figure 1b) (32). 
Nine out of 12 residues are polar, which raises 
the chances of forming hydrogen bonds with a 
ligand. There are no histidines among the 
constituting residues, yet His172 and His163 
(both as HSD) are found near Ser139, Phe140 
and Glu166. It is worth noting that the source 
material that predicted SARS-CoV-2 DS inferred 
the location of the site based on SARS-CoV-1 DS 
(32), therefore their site description is 
perfectible by more direct studies. Similar to 
the SBS, five amino acids with charged side 
chains at physiological pH were observed 
(Table 1). 
Finally, the CS residues (Figure 1c) jointly make 
up a SASA of 665.350 Å2. Unlike DS, only half of 
the residues were polar. No histidines were 
observed inside nor in the near vicinity. 
Nevertheless, this site is the most likely to host 
saline bonds given the nine residues with 
ionizable sidechains found within (Table 1). 
3.4.   Virtual Screening 
The best 100 compounds for each putative 
binding site had mean binding energies of -
8.89, -10.06, -8.08 and -9.21 kcal/mol for the 
NSBS, the ISBS, the DS and the CS, respectively. 
Each of these ligands’ sets were selected for a 
VD against their respective putative binding 
site. 
3.5.   Validation Docking 
Mean binding energies for each site’s top fivr 
were -9.52, -11.512, -7.042 and -10.348 
kcal/mol for the NSBS, the ISBS, the DS and the 
CS, respectively. After cross-referencing the 
NSBS and ISBS top 30, a total of fifteen 
compounds were retrieved (Table 2). The final 
VD results presented the ligands Dorsilurin E 
(FL3FQUNP0001), Euchrenone a11 
(FL2FALNP0014), Kurziflavolactone C 
(FL2FA9NC0016), Licorice glycoside E 
(FL2F1AGSN001) and Taxifolin 3'- (6"-phenyl- 
acetylglucoside) (FL4DACGS0020) binding only 
Site Residue Charged Polar
Ser1* 0 Y
His41 0 Y
Met49 0 N
Tyr54 0 N
Phe140 0 N
Leu141 0 N
Asn142 0 Y
Gly143 0 N
Ser144 0 Y
Cys145 0 N
His163 0 Y
His164 0 Y
Met165 0 N
Glu166 - Y
Leu167 0 N
Pro168 0 N
Asp187 - Y
Arg188 + Y
Gln189 0 Y
Thr190 0 Y
Ala191 0 N
Gln192 0 Y
Arg4 + Y
Met6 0 N
Ser10 0 Y
Gly11 0 N
Glu14 - Y
Asn28 0 Y
Ser139 0 Y
Phe140 0 N
Ser147 0 Y
Glu166 - Y
Glu290 - Y
Arg298 + Y
Lys5 + Y
Met6 0 N
Pro108 0 N
Gly109 0 N
Arg131 + Y
Trp218 0 N
Phe219 0 N
Tyr239 0 N
Glu240 - Y
Lys271 + Y
Lys272 + Y
Lys287 + Y
Glu288 - Y
Asp289 - Y
Glu290 - Y
Gln299 0 N
Val303 0 N
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the SBS; Sanggenol O (FL2FALNP0020), CHEMBL2171573, Kanzonol E (FL3F1ANP0001), 
CHEMBL2171584 and Abyssynoflavanone VI (FL2FACNP0014) binding only the DS; 
CHEMBL2171598, CHEMBL2171577, Denticulaflavanol (FL5FAANR0001), Kurzichalcolactone 
(FL1CA9NC0001) and CHEMBL2171578 binding only CS (Figure 2). Of these compounds, seven 
flavonoids (Licorice glycoside E, Taxifolin 3'- (6"-phenylacetylglucoside), CHEMBL2171573, 
CHEMBL2171584, CHEMBL2171598, CHEMBL2171577 and CHEMBL2171578) had more than 12 
torsions, while the rest had less than eight torsions. 
  
 
 
ID Common name Site SMILE 2D-Structure
FL2FACNP0014 Abyssinoflavanone VI DS
c(c5O)c(cc(c45)OC(CC(
=O)4)c(c2)c(C1)c(c(O3)
c2CCC(C)(C)3)OC(C1O)
(C)C)O
FL3F1ANP0001 Kanzonol E DS
c(c4)(CC=C(C)C)c(cc(c4
3)OC(=CC3=O)c(c1)cc(
C=2)c(OC(C2)(C)C)c1)O
FL2F1AGSN001 Licorice glycoside E SBS
c(OC(O4)C(OC(O5)
C(O)C(COC(=O)c(c
76)cnc6cccc7)(C5)O
)C(C(C4CO)O)O)(c1
)ccc(C(O2)CC(c(c3)
c2cc(c3)O)=O)c1
FL2FALNP0014 Euchrenone a11 SBS
O=C(c31)CC(c(c5O)cc(c
4c5)C=CC(O4)(C)C)Oc1
c(CC=C(C)C)c(c2c3O)O
C(C=C2)(C)C
FL2FALNP0020 Sanggenol O DS
c(C(C4)Oc(c5)c(c(cc5O
)O)C4=O)(c23)cc(c1c(C
=CC(C)(C)O3)2)C=CC(C
)(C)O1
FL3FQUNP0001 Dorsilurin E SBS
c(c54)(O6)c(CCC6(C)C)
c(c2c4OC(CC5)(C)C)OC
(=c(c3)c(=O)cc(O)c3)C(
=C21)CCC(C)(C)O1
Table 2. List and 2D structure of top flavonoid hits. 
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The common name, code, SMILE, 2D structure of each flavonoid is indicated, along with the putative binding site it binds to. 
CHEMBL2171573 NA DS
Cc1ccc(COc2cc(OCc3cc
c(C)cc3)cc(-
c3cc(=O)c4ccc(OCC(O)
CNC(C)(C)C)cc4o3)c2)c
c1
CHEMBL2171577 NA CS
CC(C)(C)NCC(O)COc1cc
c2c(=O)cc(-
c3cc(OCc4cc(Cl)cc(Cl)c
4)cc(OCc4cc(Cl)cc(Cl)c
4)c3)oc2c1
CHEMBL2171598 NA CS
O=c1cc(-
c2cc(OCc3ccccc3)cc(O
Cc3ccccc3)c2)oc2cc(O
CC(O)CN3CCN(c4ccccc
4)CC3)ccc12
FL1CA9NC0001 Kurzichalcolactone CS
c(c5)ccc(c5)C=CC(C3)(
OC(C4)CCCC(Oc(c2C34
)cc(c(c(O)2)C(C=Cc(c1)
cccc1)=O)O)=O)O
FL2FA9NC0016 Kurziflavolactone C SBS
C(C3=O)CCC(O1)C
C(c(c4O)c(cc(O5)c(
C(=O)CC(c(c6)cccc
6)5)4)O3)CC1(C=Cc
(c2)cccc2)O
CHEMBL2171578 NA CS
CC(C)NCC(O)COc1ccc2
c(=O)cc(-
c3cc(OCc4cc(Cl)cc(Cl)c
4)cc(OCc4cc(Cl)cc(Cl)c
4)c3)oc2c1
FL5FAANR0001 Denticulaflavonol CS
c(C(O2)=C(C(c(c(O)3)c
2cc(c3CC=C(C)CCC(C5(
C)4)C(=C)CCC4C(CCC5)
(C)C)O)=O)O)(c1)ccc(c
1)O
CHEMBL2171584 NA DS
CC(C)(C)NC[C@H](O)C
Oc1ccc2c(=O)cc(-
c3cc(OCc4ccccc4)cc(O
Cc4ccccc4)c3)oc2c1
FL4DACGS0020
Taxifolin 3'- (6"-
phenylacetylglucosi
de)
SBS
c(c1)(O)cc(c(C(=O)2)c1
OC(c(c3)ccc(O)c(OC(O
4)C(O)C(C(C(COC(Cc(c
5)cccc5)=O)4)O)O)3)C
2O)O
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Remarkably, all SBS-binding ligands interacted with one catalytic residue (His41) mentioned in 
previous literature (Table 3). Among the most energy-favoured hits for SBS, Dorsilurin E 
presented the best binding energy to ISBS (-11.31 kcal/mol). The same compound showed a 
binding energy of -9.51 kcal/mol in the NSBS. This compound interacted through a hydrogen 
bond with residue Gln192 from ISBS from a 2.06 Å distance. Besides, hydrophobic interactions 
with residues His41, Met49, Met165, Glu166, Leu167, Pro168, and Gln189 were observed, which 
favour complex stabilization. The estimated Kd to the ISBS was 4.78 nM, whereas in the NSBS it 
was 100.87 nM, for the best inhibitor. 
For DS, Sanggenol O was the single best putative inhibitor with a binding energy of -7.29 
kcal/mol and a Kd of 4334.61 nM. This energy value was lower than the binding energies for the 
top hits in the other two putative binding sites. Sanggenol O presented four hydrogen bonds 
(with residues Met6, Ser113, Gln127 and Arg298 from 2.12, 3.25, 2.60 and 2.21 Å distances, 
respectively), along with four hydrophobic interactions (Phe8, Pro9, Thr304 and Phe305) (Table 
3). Surprisingly, all DS hits inserted at least one of their aromatic rings into a novel pocket 
comprised by DS and CS residues Met6, Glu290, Arg298; by residues exclusive to CS: Lys5 and 
Val303; and other residues not included in any site: Ala7, Phe8, Ser113, Gln127, Phe291, Asp295 
(Figure 3). The cavity is also present in other crystal structures of the free MPRO (PDB IDs: 6XB1, 
6XHU, 6Y2E, 6M2Q, 6Y84 and 7BRO). Interestingly, the mentioned pocket disappears in 6LU7 
(MPRO complexed with inhibitor N3). However, in other MPROs complexed with different 
inhibitors, the novel pocket is present fully or to some degree (PDB IDs: 6M2N, 6WTT, 6XMK, 
6M0K, 6W63, 6XBG). 
Figure 3. Close-up of the novel pocket in the dimer binding site. The surface of residues comprising the novel pocket are shown in 
red, whereas the rest of the protein’s surface is in cyan. A representative compound from those tested against dimerization and 
cryptic sites, CHEMBL2171598, is shown in magenta sticks as it introduces an aromatic ring into the novel cavity. 
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Site Ligand Torsions ΔG Kd (nM) Residue Ligand atom
Distance
(Å) Acceptor Donor
Distance
(Å) Type Residue
Ligand 
atoms Distance
His41 C8 3.31 O35 Gln192 2.06
Met49 C7 3.94
Met165 C3 3.47
Glu166 C21 3.17
Leu167 C29 3.99
Pro168 C27 3.85
Gln189 C3 3.70
His41 C24 3.81 Glu166 O35 1.94
Met49 C25 3.81 O36 Glu166 2.02
Phe140 C30 3.85
Leu141 C14 3.41
Met165 C15 3.64
Asp187 C24 3.27
Thr25 C15 3.82 Leu141 O38 1.99
Leu141 C23 3.60 O39 Gly143 2.36
Asn142 C31 3.79 Gly143 O39 3.50
Met165 C3 3.55 O39 Cys145 1.77
Glu166 C4 3.76 O34 His163 2.23
Val303 C23C24
3.34
3.07
Thr25 C15 3.37 O41 Thr26 1.86
Met165 C22 3.29 O42 His41 3.08
Pro168 C32 3.48 O43 Gly143 2.44
Gln189 C23 3.68 O50 Ser144 3.09
Ser144 O50 2.74
O48 Ser144 2.93
O50 His 163 2.04
O37 Glu166 3.12
O46 Gln192 2.54
Phe140 C18 3.25 O40 Tyr54 2.58
Met165 C24 3.52 His164 O41 2.49
Glu166 C16 3.41 O42 Glu166 1.80
Gln189 C23 3.51 Glu166 O42 2.13
Gln192 C4 3.77 Asp187 O40 2.18
Thr190 O37 1.99
O37 Gln192 2.17
Phe8 C23 3.41 Met6 O30 44167
Pro9 C6 3.35 O30 Ser113 3.25
Thr304 C12 3.70 O30 Gln127 2.60
Phe305 C3C18
3.48
3.65 O31 Arg298 2.21
Met6 C28 3.92 N1 Ser10 3.28
Pro9 C11C7
3.89
3.87 O42 Ser10 2.35
Val125 C15 3.16 Ser10 O43 1.91
Phe291 C30 3.80 O43 Gly11 2.62
Asp295 C30 3.53 Glu14 N1 2.61
Gln299 C37C27
3.34
3.5
Phe305 C3 3.62
Phe3 C25 3.46 Met6 O29 2.02
Met6 C24 3.60 O29 Gln127 3.72
Phe8 C4 3.57
Pro9 C16 3.29
Phe291 C24C25
3.10
3.14
Asp295 C22 3.07
Arg298 C6 3.98
Gln299 C25 3.63
Thr304 C12 3.45
Phe305 C10C15
3.92
3.13
Pro9 C10C11
3.67
3.87 Ser10 N1 1.76
Glu14 C35 3.92 O43 Ser10 2.79
Leu115 C37 3.27 Ser10 O43 2.47
Pro122 C35 3.42 O42 Ser10 2.58
Val125 C3 3.97
Arg298 C20 3.87
Gln299 C28C20
3.46
3.39
Phe305 C14 3.49
Pro9 C7 3.66 Met6 O30 2.04
Thr304 C8 3.76 O30 Ser113 3.23
Phe305 C25 3.68 O30 Gln127 2.63
O31 Arg298 2.18
FL3FQUNP0001
[Dorsilurin E]
FL2FA9NC0016
[Kurziflavolactone 
C]
Su
bs
tr
at
e
FL4DACGS0020
[Taxifolin 3'- (6"-
phenylacetylglucosi
de)]
FL2FALNP0014
 [Euchrenone a11]
π-Cation His41
C8, C9, 
C10, 
C11, 
C12, 
C13
5.83
Other
1
239.30*
34.70**
2201.31*
154.06**
-9.51*
-11.31**
100.87*
4.78**
5 -9.00*-10.14**
5 -8.88*-11.24**
293.25*
5.38**
16 -7.69*-9.26**
Hydrophobic Hydrogen bond
CHEMBL2171584
FL2FACNP0014
[Abyssinoflavano-
ne VI]
4.18
FL2F1AGSN001
[Licorice glycoside 
E]
π-Stacking His41
C22, 
C23, 
C24, 
C25, 
C26, 
C27 
4.7915 -7.21*-9.27**
4963.68*
151.47**
FL3F1ANP0001
[Kanzonol E]
π-Cation Arg298
C25, 
C26, 
C27, 
C28, 
C29, 
C31
4.81
π-Cation Arg298
C18, 
C19, 
C20, 
C21, 
C22, 
C23
4.74
π-Stacking Phe8
C18, 
C19, 
C20, 
C21, 
C22, 
C23
4 -6.92 8112.39
-6.89 8535.3014
Di
m
er
FL2FALNP0020
[Sanggenol O]
CHEMBL2171573
4 -6.83 9448.42
Table 3. Comprehensive list of protein-ligand interactions.
3 -7.29 4334.61
14 -7.28 4408.66
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Top 5 binding energy flavonoids are listed for each putative binding site. Interactions are according to PLIP predictions. ∆G and Kd 
values for the substrate binding site are marked as * for the normal docking procedure and ** for the induced-fit docking. Note that 
both ligand and protein can participate as donor or acceptor in hydrogen bonds. Thus, ligands are represented with their atom name 
and number, and protein residues are portrayed as their name and number.	
The buried rings of CHEMBL2171584 and CHEMBL2171573 sustain a cation-π interaction with 
Arg298 (Figure 2, Table 3). Abyssinoflavanone VI shows a π-π stacking with Phe8. The inserted 
rings of Abyssinoflavanone VI, Sanggenol O and Kanzonol E are substituted with hydroxyl groups. 
In both Abyssinoflavanone VI and Sanggenol O, the hydroxyl group in the position 5 of the 
backbone ring shows hydrogen bonds with Arg298. Likewise, in both flavonoids the hydroxyl 
group in the position 7 presents three hydrogen bonds with Met6, Ser113 and Gln127 (Figure 
2). Furthermore, the hydroxyl group in the position 7 of the Kanzonol E ring establishes hydrogen 
bonds with Met6 and Gln127.	
As for the CS, CHEMBL2171598 was the best inhibitor with a binding energy of -10.59 kcal/mol 
and a Kd of 16.19 nM. This compound interacted through hydrogen bonds with residues Lys5, 
Ala7 and Val125 from 2.01, 2.97 and 2.11 Å, respectively (Table 3). Likewise, it held hydrophobic 
interactions with residues Lys5, Met6, Pro9, Tyr126, Asp295, Gln299 and Phe305. Interestingly, 
Kurzichalcolactone and CHEMBL2171598 were found to bind within the novel pocket in the 
same fashion as the DS hits. 
The information regarded surface data for each hit is included in Table 4. The widest interface 
areas for SBS, DS and CS are observed in Licorice glycoside E with 553.205 Å2; CHEMBL2171573 
with 484.185 Å2; and CHEMBL2171598 with 536.563 Å2, respectively. 
 
 
Lys5 C41 3.48 Lys5 O50 2.01
Met6 C21 3.72 O49 Ala7 2.97
Pro9 C4 3.14 Val125 N1 44137
Tyr126 C44 3.88
Asp295 C22 3.54
Gln299 C21C30
3.63
3.26
Phe305 C15 3.55
Tyr237 C32C37
3.93
3.96 O41 Lys5 1.73
Asn238 C35 3.70 O38 Thr199 2.26
Tyr239 C33 3.78 O42 Leu287 2.18
Leu286
C7
C21
C23
3.47
3.21
3.14
Glu288 N1 2.92
Leu287 C7 3.95 Glu288 O41 2.02
O40 Asp289 2.44
Lys137 C7 3.69 O40 Lys5 1.97
Thr199 C15 3.85 O41 Gln127 2.28
Tyr237 C27 3.65 O39 Lys137 1.97
Tyr239 C28 3.21 Asp197 O39 2.13
Leu272 C27 3.28 Glu288 O40 1.94
Leu286 C21 3.63 O37 Glu288 2.69
Leu287 C22C18
3.68
3.52 O37 Asp289 1.82
O38 Asp289 2.05
O40 Glu290 3.47
Phe8 C29 3.82 Gly2 O36 2.04
Ile213 C22 2.95 Gln299 O37 2.03
Asp295 C31 3.75 Val303 O39 1.86
Arg298 C26 3.40 O38 Val303 2.25
Gln299 C2 3.82
Thr199 C9 3.56 O37 Arg131 2.80
Tyr237 C25 3.62 O37 Thr199 2.08
Asn238 C27 3.44 O42 Leu287 2.15
Tyr239 C7 3.66 Glu288 N1 3.14
Leu286
C22
C16
C3
3.54
3.70
3.67
Glu288 O40 1.91
Leu287 C3C5
3.61
3.57
Halogen Asp197 Donor: Cl46 3.29
π-Cation Arg131
C4, C5, 
C6, C7, 
C8, C9
4.03Cr
yp
tic
FL1CA9NC0001
[Kurzichalcolactone
]
CHEMBL2171578
CHEMBL2171598
CHEMBL2171577
FL5FAANR0001
[Denticulaflavonol] -10.44 20.87
8
14 -10.59 16.19
π-Cation Arg298
C29, 
C31, 
C28, 
C30, 
C27, 
C32
4.55
Halogen Asp197 Donor: Cl44 3.7514 -9.97 46.28
-10.23 29.79
14 -10.51 18.54
10
 14 
 
Measure of the protein/ligand interface areas expressed in Å² for all 15 hit flavonoids with their respective putative binding sites. 
Standard deviations provided for comparison.	
3.6.   Positive and negative controls 
The inhibitory ligand X77 successfully docked against the ISBS of the free MPRO (-10.77 kcal/mol). 
A structural alignment between the ligands on the docked structure and the original 6W63 
crystal revealed a relatively low deviation from the original (RMSD: 1.352 and 1.693 Å, with and 
without hydrogens, respectively), considering that the docked ligand was not the original 
inhibitor (N3) from the employed induced conformation (Figure 4). As for the negative control, 
the best pose according to the 2Dscore had an energy of -5.46 kcal/mol. 
 
Figure 4. Structural alignment between the positive control and the original MPRO crystal. Docked inhibitory ligand was aligned to 
the original MPRO crystal (PDB: 6W63), revealing an RMSD of 1.352 Å. A close-up is provided such as to observe the docked pose in 
detail compared to the original position. The MPRO crystal is shown as in Figure 1. The ligand is shown in sticks: orange for the control 
and ice blue for the cross-docked X77.	
SBS DS CS
FL3FQUNP0001 Dorsilurin E 446.243 --- ---
FL2FALNP0014  Euchrenone a11 455.602 --- ---
FL2FA9NC0016 Kurziflavolactone C 450.332 --- ---
FL2F1AGSN001 Licorice glycoside E 553.205 --- ---
FL4DACGS0020 Taxifolin 3'- (6"-phenylacetylglucoside) 452.283 --- ---
FL2FALNP0020 Sanggenol O --- 332.971 ---
CHEMBL2171573 NA --- 484.185 ---
FL3F1ANP0001 Kanzonol E --- 360.737 ---
CHEMBL2171584 NA --- 482.063 ---
FL2FACNP0014 Abyssinoflavanone VI --- 323.374 ---
CHEMBL2171598 NA --- --- 536.563
CHEMBL2171577 NA --- --- 497.366
FL5FAANR0001 Denticulaflavonol --- --- 477.840
FL1CA9NC0001  Kurzichalcolactone --- --- 428.060
CHEMBL2171578 NA --- --- 505.758
DS
CS
Table 4. Protein/Ligand interface areas. 
Site Ligand Name Interface Ligand/Protein (Å
2 )
SBS
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4.  DISCUSSION 
4.1.   Structure 
The MPRO binding sites analysis have provided new insights regarding the chemical 
microenvironments of the structure. Based on the aforementioned pKa’s of HSD and HSE, the 
pH range needed for the coexistence of these two protonation states is 6.7-7.3. Hence, SBS 
microenvironment’s pH is acidic with respect to the pH 7.4 of the general system. Additionally, 
His172 is proximate to His163, the latter belonging to SBS. His172 is also protonated in the HSD 
position. Given the proximity of these two 6.5 pKa residues (7.6 Å between alpha carbons), there 
is more reason to believe in the relative acidity of the SBS. Moreover, the presence of two 
adjacent histidines with divergent tautomeric states (His163 in HSD and His164 in HSE) suggests 
said microenvironment can be further divided, being the region around His163 (S1) more acidic 
than the region around His164 (S2). Said difference is reasonable as His163 is closer to the 
catalytic subsite S1’. This acidic microenvironment could ease proteolysis as it has been reported 
that the optimum pH range for catalytic sites in other cysteine-proteases is 5-6 (58–60).  Sizeable 
changes in the microenvironment pH could thus lead to partial or total loss of catalytic function. 
Therefore, a ligand designed to not just bind the SBS but to change local pH is a hypothetical, 
but realistic goal for drug designers. 
Similar conditions are found in a DS subregion comprising Ser139, Phe140 and Glu166. His163 
and His172, close to the aforementioned DS subregion, are in HSD tautomeric state, suggesting 
an acidic microenvironment for this DS subsection. In contrast, no histidines were observed near 
or within the CS. 
Then, Table 1 shows CS has the highest number of charged residues and thus stands a better 
chance of establishing saline bonds with an appropriate ligand. The absence of this type of 
interaction among the other compounds is explained by the electrochemically neutral nature of 
the hits. Future attempts at drug design might benefit from avoiding electrochemical neutrality 
for a greater chance of saline bond formation in this region. 
4.2.   Docking 
As has already been mentioned, Table 3 contains binding energies which suggest likelihood of 
effective binding. To take these numbers at face value could be misleading, however. Besides 
binding energy, binding location and interaction density should also be accounted for. In 
particular, for the SBS docking, the more subsites a ligand interacts with in a wider area, the 
higher the chance of proper inhibition, as the cavities needed for the proper accommodation of 
the natural substrate of MPRO would be sterically obstructed. 
For instance, besides a handsome binding energy, Dorsilurin E forms one hydrogen bond and 
seven   hydrophobic interactions with five different SBS subsites (S1’, S2, S3, S4 and S5) (Figure 
3). By contrast, Euchrenone a11 forms two hydrogen bonds but with the same residue, although 
hydrophobic interactions are found in fewer subsites (S1’, S1, S2 and S3). Similarly, 
Kurziflavolactone C has five hydrogen bonds, seven hydrophobic interactions (two with the same 
residue) and a cation-π interaction, but only maintains contact with S1’, S1 and S3 besides two 
residues outside SBS proper. Although they present the least binding energy, Licorice glycoside 
E and Taxifolin 3'-(6"-phenylacetylglucoside) presented the most hydrogen bonds in the SBS 
(nine and seven, respectively). Licorice glycoside E interacts thus with S1’, S1, S3 and S4 and via 
hydrophobic interactions with S3, S4 and S5. Besides, it holds a hydrogen bond and a 
hydrophobic interaction with two separate residues outside SBS proper. Taxifolin 3'-(6"-
phenylacetylglucoside) holds hydrogen bonds with S2, S3 and S4; hydrophobic interactions with 
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S1, S3 and S4; and a π-stacking with S1’. Because a wider array of subsites could enhance steric 
competitiveness, Licorice glycoside E stands a substantial chance at inhibition despite not 
showing the greatest binding energy. 
It is worth noting all the SBS hits show hydrophobic interactions with Glu166, a residue which 
interacts with the N-terminus domain of the second protomer (56). This intercatenary 
interaction allows for the stabilization of SBS conformation (in the S1 subsite), which is necessary 
for MPRO proteolytic activity (61,62). Based on this, it is highly likely that ligands interacting with 
Glu166 may cause structural modifications on the catalytic site and hinder activity. In addition, 
π-π stacking interactions were observed between two compounds, Kurziflavolactone C and 
Taxifolin 3'-(6"-phenylacetylglucoside), and His41, the latter being one of the catalytic residues 
of SBS. His41 is protonated as HSD. Said tautomer prevails in this region’s acidic pH. A slight 
variation in this microenvironment could change the protonation states and modify the 
aforementioned interaction. For example, a change in His41 from HSD (single protonation) to 
HIS+ (double protonation) could intensify bond interaction (63). However, π-π stackings are 
generally weak. Further insights are needed to assess the real contribution to ligand binding by 
these interactions. 
A last note-worthy point on SBS is that two hits involve glycosylated flavonoids (Licorice 
glycoside E and Taxifolin 3'-(6"-phenylacetylglucoside)). A previous study on SARS-CoV-1 3CLPRO 
reported two glycosylated flavonoids as inhibitors, whose sugar moieties interacted with the 
active sites’s S1 and S2 subsites through hydrogen bonds (31). Nonetheless, only Licorice 
glycoside E’s sugar moieties exhibited any interactions whatsoever: hydrogen bonds with His41 
(S1’), Gly143 (S1’), Ser144 (S1’), His 163 (S1) and Gly166 (S3). While the visualization tools 
suggested a non-interactional occupation of S3 by Taxifolin 3'-(6"-phenylacetylglucoside), there 
is stark contrast with the results reported by the aforementioned study. The differences in sugar-
receptiveness between analogous subsites could be illuminating for future studies aiming at 
deeper comparative analyses between both proteases. 
Further along the line, the MPRO DS is presented as a remarkably druggable site for possible 
inhibition, since a close correlation between the dimerization process and the proteolytic 
activity has been indicated (64). Remarkably, all the DS hits interacted with highly conserved 
residues among coronaviruses, namely Arg4, Met6, Gly11, Gly14, Ser10, and Arg298 (32). Under 
this view, hydrogen bonds might interfere with the dimerization and might be key for future 
coronavirus inhibitors development (Figure 2, Table 3). Remarkably, all the DS hits interacted at 
least one of the DS residues which are highly conserved among coronaviruses, namely Arg4, 
Met6, Gly11, Gly14, Ser10, and Arg298 (32) (Table 3). 
Additionally, the binding modes observed in those compounds revealed a cavity partially 
spanning both DS and CS showing high affinity for substituted and unsubstituted aromatic rings. 
According to the ring’s substitutions, the pocket would allow for π-π and cation-π interactions 
as well as hydrogen bonds. Both cation-π interactions and hydrogen bonds involve at least one 
polar group whereas π-π stackings could be present between exclusively nonpolar groups. As 
the novel pocket has the possibility to form any of these interactions, it must have affinity for 
both nonpolar or polar moieties. Therefore, the novel pocket has an amphipathic nature. This is 
coherent with the other results, as the introduced rings can be either hydrophobic (phenyl rings) 
or hydrophilic (phenyl rings substituted with hydroxyl groups). 
The CS may be visually divided in two regions: the first comprised by residues shared with the 
novel pocket (Lys5, Met6, Gln290, Arg298 and Val303), and the second conformed by the 
remaining residues (Pro108, Gly109, Arg131, Trp218, Phe219, Tyr239, Glu240, Leu271, Leu272, 
Leu287, Glu288, Asp289, Glu290 and Gln299). Five of the 11 novel pocket residues are shared 
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with the CS, and thus have higher CryptoSite scores than the recommended threshold (28). 
Although this suggests a cryptic nature for this new cavity, further analysis to confirm the reality 
of the pocket is wanting. By definition, a cryptic site is one that forms in holo structure, but not 
in the apo structure (28). As the novel cavity was also present in the apo structure of some 
crystal structures of the MPRO (PDB IDs: 6XB1, 6XHU, 6Y2E, 6M2Q, 6Y84 and 7BRO it would be 
necessary to see a dramatic modification of this region upon ligand binding over time. Cavity 
expansion and ligand engulfing upon binding would count as sufficient evidence to formally 
propose the cavity as a novel cryptic site. Thus, it would be reasonable to submit the systems of 
the presented best hits to molecular dynamics simulations. Such a method would allow us to 
evaluate the systems’ mechanics and free energy profiles. In contrast to apo-MPRO, where a free 
energy local minimum is expected at the novel pocket region, it is presumed that the hits that 
interacted with said region are able to induce a higher energy conformation and stabilize the 
pocket (65).  
Unlike the novel pocket, the second CS region forms no observable cavity in the apo-MPRO.  If a 
cavity is then formed upon ligand binding, this region would fit the definition of cryptic site 
better than the novel pocket. However, as it is the case with the novel cavity, to see this 
formation and settle the cryptic nature of this second region, it would be necessary to submit 
the systems to molecular dynamics. 
In other considerations, binding energy is not the only factor to take into account, as interface 
area between ligand and protein in complex is important as well. In short, more interface area 
involves less SASA, as the ligand buries more protein area. A greater interface area generally 
enjoys three advantages. First, the ability to sterically compete with the native substrate for the 
SBS is enhanced as less SASA is present for the natural substrate after the binding event. This 
fact is closely related to the previously mentioned occupation of the SBS subsites. Second, as 
the ligand occupies more protein surface, more interfacial water is dispersed and “reinserted” 
into the solvent, thus partly offsetting the entropic diminishment from ligand binding and 
preserving the second law of thermodynamics (66). Another contribution to this compensation 
is an increase in the number of conformational degrees of freedom of the protein itself (67,68). 
This is the third advantage: a wider contact surface area for the ligand might make it easier to 
alter the native enzyme conformation for the MPRO and achieve more degrees of freedom. Said 
correlation has been observed both in protein-protein complexes (69) and individual subunits 
(70) as a relation between interface surface and sizable conformational change (71). It is 
suggestive to imagine a similar relationship with regard to protein-ligand complexes. Therefore, 
while there is not much difference among the interface areas projected by SBS and CS ligands, 
DS ligands show greater standard deviation.If interface area is therefore taken as an important 
variable for inhibition, Licorice glycoside E and CHEMBL2171598 could be most promising for 
SBS and CS, respectively. 
5.      CLOSING REMARKS 
Flavonoids have already been suggested as potential inhibitors of the SARS-CoV MPRO, showing 
a high affinity for their hydrophobic aromatic rings and hydrophilic hydroxyl groups (31). In the 
present research, a group of 15 flavonoids has been identified as possible SARS-CoV-2 MPRO 
inhibitors. Said group shares some structural similarities with those proposed as SARS-CoV-1 
inhibitors. Besides, these compounds have been evaluated against different binding sites in MPRO 
(SBS, DBS and CBS), and the resulting binding energies were favourable for flavonoid-protein 
complexes.  
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Molecular dynamics of the 15 compounds with their respective putative binding sites are 
currently under way. Moreover, the complete, dimeric structure of MPRO  is being considered for 
SBS as this site is stabilized by both protomers (61,62). Nonetheless, experimental validations 
are still required to vouch for the effectiveness of the presented compounds as true SARS-CoV-
2 inhibitors. Not only PAINS, but colloidal aggregates could induce false positives (53,54), calling 
for the application of surface tension reduction agents such as Triton-X100 or Tween-80 (72,73). 
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